BresMed White Paper: 8 Common Challenges with Rare Disease Drug Value and How to Address Them

July 29, 2020

BresMed, and international HEOR consultancy, developed a white paper exploring eight key challenges that manufacturers face when demonstrating the value of rare disease products to decision-makers.  They describe their framework for proactively overcoming these challenges so that manufacturers can achieve earlier access to market, at a price that reflects product value. A lack of head-to-head trial data can be a key challenge to demonstrating the value of drugs for rare diseases. Download the white paper that identifies 8 common challenges and a framework for overcoming them, designed by BresMed’s rare disease experts.

Download White Paper here.

Share This Story!